Psychiatr. pro Praxi, 2008; 9(6): 257-261

THE USE OF DUAL ANTIDEPRESSANTS IN THE TREATMENT OF DEPRESSIVE DISORDER

MUDr. Sylva Racková, MUDr. Luboš Janů Ph.D
Psychiatrická klinika FN a LF UK v Plzni

Depressive disorder is a very often and major psychiatric disease. Depression is possible in most patients succesfully treated using a right type of treatment. The main role in the treatment of depression play antidepressants. Dual antidepressants are in some cases more effective in comparison with other antidepressants in the acute and prophylactic phaze of treatment of depression, in the treatment of resistance depression. Dual AD have comparable tollerability. Efficacy and tolerability improve compliance which is important in the treatment of depressive disorders.

Keywords: Key words: depressive disorder, compliance, treatment, dual antidepressants, venlafaxine, duloxetine, milnacipran.

Published: December 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Racková S, Janů L. THE USE OF DUAL ANTIDEPRESSANTS IN THE TREATMENT OF DEPRESSIVE DISORDER. Psychiatr. praxi. 2008;9(6):257-261.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Acharya N, Rosen A, Polzer J, D Souza DN, Perahia DG, Cavazzoni PA, Baldessarini RJ. Duloxetine: Meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder. J Clin Psychopharmacol. 2006; 26(6): 587-594. Go to original source... Go to PubMed...
    2. Anderson IM. Meta-analytical studies on new antidepressants. British Medical Bulletin. 2001; 57: 161-178. Go to original source... Go to PubMed...
    3. Bielski RJ, Ventura D, Chang CC. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry. 2004; 65(9): 1190-1196. Go to original source... Go to PubMed...
    4. Bull SA, Hunkeler EM, Lee JY, et al. Discontinuing or switching selective serotonin-reuptake inhibitors. Ann Pharmacother. 2002; 36: 578-584. Go to original source... Go to PubMed...
    5. Claxton A, de Klerk E, Parry M, Robinson JM, Schmidt ME. Patient compliance to a new enteric-coated weekly formulation of fluoxetine during continuation treatment of major depressive disorder. J Clin Psychiatry. 2000; 61: 928-932. Go to original source... Go to PubMed...
    6. Clerg G. Antidepressant efficacy and tolerability of milnacipram, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluoxetine. Int Clin Psychopharmacol. 2001; 16(3): 145-151. Go to original source... Go to PubMed...
    7. Češková E. Duálně působící antidepresiva. Remedia 2006; 16(6): 594-597.
    8. Dunner DL, Wilson M, Fava M, Kornstein S, Munoz R, O´Reardon J, Trivedi M, Wohlreich M. Long-term tolerability and effectiveness of duloxetine in the treatment of major depressive disorder. Depression and Anxiety. 2008; 25: E1-E8. Go to original source... Go to PubMed...
    9. Eaddy M, Regan T. Real world 6-month immediate-release SSRIs non-adherence. Program and abstracts of the Disease Management Association of America 5th Annual Disease Management Leadership Forum. October 12-15, 2003; Chicago, Illinois.
    10. Eckert L, Lancon Ch. Duloxetine compared with fluoxetine and venlafaxine: use of meta-regression analysis for indirect comparisons. BMC Psychiatry. 2006; 6(30). Go to original source... Go to PubMed...
    11. Goldstein DJ, Lu Y, Derme MJ, Wiltse C, Mallinckrodt C, Demitrack MA. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol. 2004; 24(4): 389-399. Go to original source... Go to PubMed...
    12. Hansen RA, Gartlehner G, Lohr KN, Gaynes BN, Carey TS. Efficacy and Safety of SecondGeneration Antidepressants in the Treatment of Major Depressive Disorder. Ann Intern Med. 2005; 143: 415-426. Go to original source... Go to PubMed...
    13. Keene MS. Confusion and Complaints: The True Cost of Noncompliance in Antidepressant Therapy. Medscape Psychiatry & Mental Health. 2005; 10(2).
    14. Khan A, Bose A, Alexopoulos GS, Gommoll C, Li D, Sandhi Ch. Double-Blind Comparison of Escitalopram and Duloxetine in the Acute Treatment of Major Depressive Disorder. Clin Drug Invest. 2007; 27(7): 481-492. Go to original source... Go to PubMed...
    15. Kocsis JH, Thase ME, Trivedi MH, Shelton RC, Kornstein RG, Nemeroff CB, Friedman ES, Gelenberg AJ, Dunner DL, Hirschfeld RM, Rothschild AJ, Ferguson JM, Schatzberg AF, Zajecka JM, Pedersen RD, Yan B, Ahmed S, Musgung J, Ninan PT, Keller MB. Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study. J Clin Psychiatry. 2007; 68(7): 1014-1023. Go to original source... Go to PubMed...
    16. Lee SI, Keltner NL. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs): Venlafaxine and Duloxetine. Perspectives in Psychiatric Care. 2006; 42(2): 144. Go to original source... Go to PubMed...
    17. Lenox-Smith AJ, Juany O. Venlafaxine extended release versus citalopram in patiens with depression unresponsive to a selective serotonin reuptake inhibitor. Int Clin Psychopharmacol. 2008; 23(3): 113-119. Go to original source... Go to PubMed...
    18. Lin EH, Von Korff M, Katon W, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care. 1995; 33: 67-74. Go to original source... Go to PubMed...
    19. Machado M, Iskedjian M, Ruiz I, Einarson TR. Remission, dropouts and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials. Curr Med Res Opin. 2006; 22(9): 1825-1832. Go to original source... Go to PubMed...
    20. Montgomery Sa, Entsuah R, Hackett D, Kunz NR, Rudolph RL. Venlafaxine 335 Study Group. Venlafaxine versus placebo in the preventive treatment of recurrent major depression. J Clin Psychiatry. 2004; 65(3): 328-336. Go to original source... Go to PubMed...
    21. Montgomery SA, Huusom AK, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology. 2004; 50(1): 57-64. Go to original source... Go to PubMed...
    22. Montomery SA, Prost JF, Solles A, Briley M. Efficacy of milnacipran: an overview. Int Clin Psychopharmacol. 1996; Suppl 4: 47-51. Go to original source... Go to PubMed...
    23. Okumura K, Furukawa TA. Remission rates with milnacipran 100 mg/day and 150 mg/day in the long-term treatment of major depression. Clin Drug Invest. 2006; 26(3): 135-142. Go to original source... Go to PubMed...
    24. Olfson M, Marcus SC, Tadeschi M, Wan GJ. Continuity of Antidepressant Treatment for Adults Depression in the United States. Am J Psychiatry. 2006; 163: 101-108. Go to original source... Go to PubMed...
    25. Perahia DG, Pritchett YL, Kajdasz DK, Bauer M, Jain R, Russell JM, Walker DJ, Spencer KA, Froud DM, Raskin J, Thase ME. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. J Psychiatr Res. 2008; 42(1): 22-34. Go to original source... Go to PubMed...
    26. Pigott TA, Prakash A, Arnold LM, Aaronson ST, Mallinckrodt CH, Wohlreich MM. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder. Curr Med Res Opin. 2007; Apr 27. Go to original source... Go to PubMed...
    27. Raskin J, Goldstein D, Mallinckrodt CH, Ferguson MB. Duloxetine in long-term treatment of major depressive disorder. J Clin Psych. 2003; 64(10): 1237-1244. Go to original source... Go to PubMed...
    28. Puech A, Montgomery SA, Prost JF, Solles A, Briley A. Milnacipran, a new serotonin and noradrenaline re-uptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol. 1997; 12: 99-108. Go to original source... Go to PubMed...
    29. Raboch J. Venlafaxinum. Remedia. 2005; 15(1): 23-31.
    30. Rubino A, Roskell N, Tennis P, Mines D, Wrich S, Andrews E. Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. BMJ. 2007; 334-342. Go to original source...
    31. Sechter D, Vandel P, Weiller E, Pezous N, Cabanac F, Tournoux A. A comparative study of milnacipran and paroxetine in outpatients with major depression. Journal of Affective Disorders. 2004; 83(2-3): 233-236. Go to original source... Go to PubMed...
    32. Skinner EP, Cantrell R, Chaffin J, et al. Adherences with once-daily bupropion XL versus twice-daily bupropion SR. J Am Pharm Assoc. 2005; 45: 265.
    33. Smith D, Dempster C, Glanville J, Freemantle N, Anderson I. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. B J Psychiatry. 2002; 180: 396-404. Go to original source... Go to PubMed...
    34. Thase ME, Entsuah R, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. B J Psychiatry. 2001; 178: 234-241. Go to original source... Go to PubMed...
    35. Tůma I. Duloxetin-třetí antidepresivum skupiny SNRI. Remedia. 2005; 559-562.
    36. Vis PM, van Baardewijk M, Einarson TR. Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials. Ann Pharmacother. 2005; 39(11): 1798-1807. Go to original source... Go to PubMed...
    37. Wade A, Gembert K, Florea I. A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Curr Med Res Opin. 2007; 23(7): 1605-1614. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.